2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Roberto Iacovelli, MD, PhD, discusses the key takeaways of the phase 2 ARIES trial in urothelial cancer.
Roberto Iacovelli, MD, PhD, medical oncologist, the Fondazione Policlinico Gemelli IRCCS, Rome, Italy, discusses the key takeaways of the phase 2 ARIES trial (NCT03891238) in urothelial cancer.
The ARIES trial evaluated first-line avelumab (Bavencio) in patients with metastatic and locally advanced urothelial cancer who were PD-L1 positive and unfit for cisplatin-based chemotherapy.
Findings from this study suggested avelumab demonstrated activity in urothelial cancer, Iacovelli says. Moreover, avelumab has a tolerable safety profile, Iacovelli adds.
Notably, patients with urothelial cancer who are ineligible for cisplatin-based chemotherapy tend to have a poor prognosis, and they are generally frailer, Iacovelli explains. These patients should be managed with immunotherapy and should be further studied in future clinical trials, Iacovelli concludes.